HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage TropismMichael Roche, Paul R. Gorry, Martin R. Jakobsen et al.|Journal of Virology|2011Cited by 82
Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C InfectionMartin R. Jakobsen, Paul R. Gorry, Anne Ellett et al.|PLoS ONE|2013Cited by 48
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entryMichael Roche, Paul R. Gorry, Martin R. Jakobsen et al.|Retrovirology|2011Cited by 42
Quantifying Susceptibility of CD4+ Stem Memory T-Cells to Infection by Laboratory Adapted and Clinical HIV-1 StrainsJacqueline K. Flynn, Paul R. Gorry, Geza Paukovics et al.|Viruses|2014Cited by 31
Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitrousage of alternative coreceptors during progressive HIV-1 subtype C infectionKieran Cashin, Paul R. Gorry, Martin R. Jakobsen et al.|Retrovirology|2013Cited by 22